Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schattenberg

Showing results (171-180 of 333) with videos related to

Pageof 34
Sort By:
Nature Metabolism|April 10, 2023
A proteo-transcriptomic map of non-alcoholic fatty liver disease signaturesOlivier Govaere, Megan Hasoon, Leigh Alexander, et al.
Scientific Reports|December 6, 2022
Health literacy in gastrointestinal diseases: a comparative analysis between patients with liver cirrhosis, inflammatory bowel disease and gastrointestinal cancerLeonard Kaps, Lea Omogbehin, Katharina Hildebrand, et al.
Alimentary Pharmacology & Therapeutics|October 6, 2018
Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in GermanyChristian Labenz, Yvonne Huber, Eva Kalliga, et al.
Journal of Clinical Medicine|November 25, 2023
Primary Biliary Cholangitis (PBC)-Autoimmune Hepatitis (AIH) Variant Syndrome: Clinical Features, Response to Therapy and Long-Term OutcomeMarkus Graf, Christian M Lange, Mona M Langer, et al.
Cells|January 8, 2023
PNPLA3(I148M) Inhibits Lipolysis by Perilipin-5-Dependent Competition with ATGLHagen Roland Witzel, Inga Maria Gertrud Schwittai, Nils Hartmann, et al.
BMC Gastroenterology|August 5, 2015
Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohortNiels Steinebrunner, Martin F Sprinzl, Tim Zimmermann, et al.
Journal of Hepatology|March 27, 2026
Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trialJörn M Schattenberg, Pierre Bedossa, Cynthia D Guy, et al.
Journal of Clinical Gastroenterology|November 16, 2018
Clinical Predictors for Poor Quality of Life in Patients With Covert Hepatic EncephalopathyChristian Labenz, Gerrit Toenges, Jörn M Schattenberg, et al.
JHEP Reports : Innovation in Hepatology|February 18, 2026
Longitudinal risk of cirrhosis by steatotic liver disease subtype among 1.5 million individuals in the USMai Sedki, Zeyuan Yang, Ashwani K Singal, et al.
Journal of Medical Virology|June 12, 2024
Proof of infectivity of hepatitis E virus particles from the ejaculate of chronically infected patientsMathias Schemmerer, Hans H Bock, Jörn M Schattenberg, et al.
Pageof 34

Showing results (171-180 of 333) with videos related to

Sort By:
Pageof 34
Nature Metabolism|April 10, 2023
A proteo-transcriptomic map of non-alcoholic fatty liver disease signaturesOlivier Govaere, Megan Hasoon, Leigh Alexander, et al.
Scientific Reports|December 6, 2022
Health literacy in gastrointestinal diseases: a comparative analysis between patients with liver cirrhosis, inflammatory bowel disease and gastrointestinal cancerLeonard Kaps, Lea Omogbehin, Katharina Hildebrand, et al.
Alimentary Pharmacology & Therapeutics|October 6, 2018
Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in GermanyChristian Labenz, Yvonne Huber, Eva Kalliga, et al.
Journal of Clinical Medicine|November 25, 2023
Primary Biliary Cholangitis (PBC)-Autoimmune Hepatitis (AIH) Variant Syndrome: Clinical Features, Response to Therapy and Long-Term OutcomeMarkus Graf, Christian M Lange, Mona M Langer, et al.
Cells|January 8, 2023
PNPLA3(I148M) Inhibits Lipolysis by Perilipin-5-Dependent Competition with ATGLHagen Roland Witzel, Inga Maria Gertrud Schwittai, Nils Hartmann, et al.
BMC Gastroenterology|August 5, 2015
Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohortNiels Steinebrunner, Martin F Sprinzl, Tim Zimmermann, et al.
Journal of Hepatology|March 27, 2026
Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trialJörn M Schattenberg, Pierre Bedossa, Cynthia D Guy, et al.
Journal of Clinical Gastroenterology|November 16, 2018
Clinical Predictors for Poor Quality of Life in Patients With Covert Hepatic EncephalopathyChristian Labenz, Gerrit Toenges, Jörn M Schattenberg, et al.
JHEP Reports : Innovation in Hepatology|February 18, 2026
Longitudinal risk of cirrhosis by steatotic liver disease subtype among 1.5 million individuals in the USMai Sedki, Zeyuan Yang, Ashwani K Singal, et al.
Journal of Medical Virology|June 12, 2024
Proof of infectivity of hepatitis E virus particles from the ejaculate of chronically infected patientsMathias Schemmerer, Hans H Bock, Jörn M Schattenberg, et al.
Pageof 34